NASDAQ:AZRX - AzurRx BioPharma Stock Price, News, & Analysis

$1.79
+0.22 (+14.01 %)
(As of 06/18/2019 03:14 PM ET)
Today's Range
$1.59
Now: $1.79
$1.79
50-Day Range
$1.43
MA: $2.27
$2.90
52-Week Range
$1.00
Now: $1.79
$3.75
Volume800 shs
Average Volume120,204 shs
Market Capitalization$37.70 million
P/E RatioN/A
Dividend YieldN/A
Beta2.74
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AZRX
CUSIPN/A
Phone646-699-7855

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.26 per share

Profitability

Net Income$-13,530,000.00

Miscellaneous

Employees12
Market Cap$37.70 million
Next Earnings Date8/9/2019 (Estimated)
OptionableNot Optionable

Receive AZRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.

AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions

What is AzurRx BioPharma's stock symbol?

AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."

When is AzurRx BioPharma's next earnings date?

AzurRx BioPharma is scheduled to release their next quarterly earnings announcement on Friday, August 9th 2019. View Earnings Estimates for AzurRx BioPharma.

What price target have analysts set for AZRX?

6 brokerages have issued 1 year price objectives for AzurRx BioPharma's stock. Their predictions range from $5.00 to $10.50. On average, they expect AzurRx BioPharma's stock price to reach $7.5833 in the next twelve months. This suggests a possible upside of 323.6% from the stock's current price. View Analyst Price Targets for AzurRx BioPharma.

What is the consensus analysts' recommendation for AzurRx BioPharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AzurRx BioPharma.

What are Wall Street analysts saying about AzurRx BioPharma stock?

Here are some recent quotes from research analysts about AzurRx BioPharma stock:
  • 1. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $189M, which includes a discounted cash flow-based asset value of $190M for MS1819, using a 15% discount rate and 2% terminal growth rate, excluding debt, with 50% probability of success." (5/24/2019)
  • 2. Maxim Group analysts commented, "AzurRx announced that its Phase 2 OPTION trial of MS1819-SD for EPI in cystic fibrosis (CF) is now over 50% enrolled. The timeline for data remains on track for mid-2019, with read out expected in the summer. Unlike current standard of care porcine-derived pancreatic enzymes (PPEs), MS1819-SD is a yeast-derived recombinant lipase which has shown a favorable safety profile so far. It may be able to reduce pill burden and improve QoL in CF patients with exocrine pancreatic insufficiency (EPI). Conclusion. We view the news as a positive for the company as the Phase 2 OPTION data this summer represents an important catalyst for AZRX shares that can drive valuation." (4/24/2019)

Has AzurRx BioPharma been receiving favorable news coverage?

News articles about AZRX stock have trended neutral recently, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AzurRx BioPharma earned a media sentiment score of 0.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for AzurRx BioPharma.

Are investors shorting AzurRx BioPharma?

AzurRx BioPharma saw a increase in short interest in May. As of May 31st, there was short interest totalling 260,100 shares, an increase of 92.1% from the April 30th total of 135,400 shares. Based on an average trading volume of 108,200 shares, the days-to-cover ratio is presently 2.4 days. Approximately 2.3% of the company's stock are short sold. View AzurRx BioPharma's Current Options Chain.

Who are some of AzurRx BioPharma's key competitors?

What other stocks do shareholders of AzurRx BioPharma own?

Who are AzurRx BioPharma's key executives?

AzurRx BioPharma's management team includes the folowing people:
  • Mr. Johan M. Spoor, Pres, CEO & Director (Age 47)
  • Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA, CFO & Director (Age 55)
  • Mr. Daniel Dupret, Chief Scientific Officer (Age 63)
  • Dr. Mathieu Schué Ph.D., Head of Laboratory
  • Dr. James E. Pennington, Chief Medical Officer (Age 76)

When did AzurRx BioPharma IPO?

(AZRX) raised $15 million in an IPO on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO.

Who are AzurRx BioPharma's major shareholders?

AzurRx BioPharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include Waldron Private Wealth LLC (0.38%) and Regentatlantic Capital LLC (0.10%). Company insiders that own AzurRx BioPharma stock include Charles J Casamento, Edmund Burke Jr Ross, Johan M Spoor, Maged Shenouda and Pelican Partners Llc. View Institutional Ownership Trends for AzurRx BioPharma.

Which institutional investors are buying AzurRx BioPharma stock?

AZRX stock was bought by a variety of institutional investors in the last quarter, including Waldron Private Wealth LLC and Regentatlantic Capital LLC. Company insiders that have bought AzurRx BioPharma stock in the last two years include Charles J Casamento, Edmund Burke Jr Ross, Johan M Spoor and Maged Shenouda. View Insider Buying and Selling for AzurRx BioPharma.

How do I buy shares of AzurRx BioPharma?

Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AzurRx BioPharma's stock price today?

One share of AZRX stock can currently be purchased for approximately $1.79.

How big of a company is AzurRx BioPharma?

AzurRx BioPharma has a market capitalization of $37.70 million. The company earns $-13,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. AzurRx BioPharma employs 12 workers across the globe.View Additional Information About AzurRx BioPharma.

What is AzurRx BioPharma's official website?

The official website for AzurRx BioPharma is http://www.azurrx.com/.

How can I contact AzurRx BioPharma?

AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]


MarketBeat Community Rating for AzurRx BioPharma (NASDAQ AZRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  252
MarketBeat's community ratings are surveys of what our community members think about AzurRx BioPharma and other stocks. Vote "Outperform" if you believe AZRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel